| 004480/0098/m1/eu/10-cover/ema/ema-cover.pdf |
903 KB |
| 004480/0098/m1/eu/10-cover/ema/ema-tracking.pdf |
123 KB |
| 004480/0098/m1/eu/12-form/ema/ema-form-eaf.pdf |
392 KB |
| 004480/0098/m1/eu/12-form/ema/ema-form-annex-var-guidance.pdf |
53 KB |
| 004480/0098/m1/eu/12-form/ema/ema-form-annex-mla.pdf |
584 KB |
| 004480/0098/m1/eu/12-form/ema/ema-form-annex-present-proposed.pdf |
382 KB |
| 004480/0098/m1/eu/12-form/ema/ema-form-annex-comp-tables.pdf |
69 KB |
| 004480/0098/m1/eu/12-form/ema/ema-form-annex-orphanec.pdf |
45 KB |
| 004480/0098/m1/eu/12-form/ema/ema-form-annex-514-pei-fahmp.pdf |
90 KB |
| 004480/0098/m1/eu/13-pi/131-spclabelpl/ema/en/ema-combined-h-4480-en.pdf |
650 KB |
| 004480/0098/m1/eu/13-pi/134-consultation/ema/ema-consultation-zuma-5.pdf |
60 KB |
| 004480/0098/m1/eu/14-expert/142-nonclinical/nonclinical.pdf |
633 KB |
| 004480/0098/m1/eu/14-expert/143-clinical/clinical.pdf |
433 KB |
| 004480/0098/m1/eu/15-specific/153-data-market-exclusivity/datamarketexclusivity-zuma-5.pdf |
429 KB |
| 004480/0098/m1/eu/16-environrisk/162-gmo/gmo.pdf |
16.4 MB |
| 004480/0098/m1/eu/16-environrisk/162-gmo/gmo-expert-signature-cv.pdf |
276 KB |
| 004480/0098/m1/eu/17-orphan/171-similarity/similarity-report-gazyvaro.pdf |
100 KB |
| 004480/0098/m1/eu/17-orphan/172-market-exclusivity/marketexclusivity-zuma-5.pdf |
55 KB |
| 004480/0098/m1/eu/18-pharmacovigilance/182-riskmgt-system/riskmgtsystem.pdf |
11 MB |
| 004480/0098/m1/eu/19-clinical-trials/clinicaltrials-zuma-5.pdf |
58 KB |
| 004480/0098/m1/eu/110-paediatrics/paediatrics-p-0132-2020.pdf |
482 KB |
| 004480/0098/m2/22-intro/introduction-zuma-5.pdf |
76 KB |
| 004480/0098/m2/24-nonclin-over/nonclinical-overview-zuma-5.pdf |
437 KB |
| 004480/0098/m2/25-clin-over/clinical-overview-zuma-5.pdf |
1.2 MB |
| 004480/0098/m2/26-nonclin-sum/introduction-zuma-5.pdf |
604 KB |
| 004480/0098/m2/26-nonclin-sum/toxicology-written-summary-zuma-5.pdf |
157 KB |
| 004480/0098/m2/26-nonclin-sum/toxicology-tabulated-summary-zuma-5.pdf |
104 KB |
| 004480/0098/m2/27-clin-sum/summary-biopharm-zuma-5.pdf |
95 KB |
| 004480/0098/m2/27-clin-sum/summary-clin-pharm-zuma-5.pdf |
820 KB |
| 004480/0098/m2/27-clin-sum/summary-clin-efficacy-zuma-5.pdf |
1.7 MB |
| 004480/0098/m2/27-clin-sum/summary-clin-safety-zuma-5.pdf |
741 KB |
| 004480/0098/m2/27-clin-sum/literature-references-zuma-5.pdf |
101 KB |
| 004480/0098/m2/27-clin-sum/synopses-indiv-studies-zuma-5.pdf |
92 KB |
| 004480/0098/m4/42-stud-rep/423-tox/4233-genotox/42332-in-vivo/4-2-3-3-2/report.pdf |
1.1 MB |
| 004480/0098/m4/43-lit-ref/biasco-2011-embomolmed.pdf |
787 KB |
| 004480/0098/m4/43-lit-ref/chang-2016-molther.pdf |
2.9 MB |
| 004480/0098/m4/43-lit-ref/cooper-2003-blood.pdf |
572 KB |
| 004480/0098/m4/43-lit-ref/finney-1998-jimmunol.pdf |
96 KB |
| 004480/0098/m4/43-lit-ref/fraietta-2018-nature.pdf |
3.6 MB |
| 004480/0098/m4/43-lit-ref/johnson-2009-blood.pdf |
332 KB |
| 004480/0098/m4/43-lit-ref/kochenderfer-2009-jimmunother.pdf |
787 KB |
| 004480/0098/m4/43-lit-ref/kochenderfer-2010-blood.pdf |
656 KB |
| 004480/0098/m4/43-lit-ref/kochenderfer-2017-jclinoncol.pdf |
1 MB |
| 004480/0098/m4/43-lit-ref/kochenderfer-2017-molther.pdf |
804 KB |
| 004480/0098/m4/43-lit-ref/leonard-2001-curropinoncol.pdf |
283 KB |
| 004480/0098/m4/43-lit-ref/locke-2019-lancetoncol.pdf |
135 KB |
| 004480/0098/m4/43-lit-ref/neelapu-2017-nengljmed.pdf |
388 KB |
| 004480/0098/m4/43-lit-ref/nicholson-1997-molimmunol.pdf |
674 KB |
| 004480/0098/m4/43-lit-ref/olejniczak-2006-immunolinvest.pdf |
302 KB |
| 004480/0098/m4/43-lit-ref/restifo-2012-natrevimmunol.pdf |
1.2 MB |
| 004480/0098/m4/43-lit-ref/rodriguez-1994-hematoloncol.pdf |
268 KB |
| 004480/0098/m4/43-lit-ref/shah-2019-bloodadv.pdf |
1014 KB |
| 004480/0098/m4/43-lit-ref/uckun-1988-blood.pdf |
1.2 MB |
| 004480/0098/m4/43-lit-ref/zola-1988-immunolcellbiol.pdf |
3.1 MB |
| 004480/0098/m4/43-lit-ref/zola-1989-immunology.pdf |
553 KB |
| 004480/0098/m4/43-lit-ref/zola-1991-immunolcellbiol.pdf |
2.5 MB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/study-report-5314/method-val-5314-zuma-5.pdf |
403 KB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/study-report-5314/method-val-5314-zuma-5-add.pdf |
108 KB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/bioagilytix-bal-19-187-064-rep/method-val-bal-19-187-064-rep.pdf |
3.6 MB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/bioagilytix-bal-20-187-063-rep/method-val-bal-20-187-063-rep.pdf |
721 KB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/bioagilytix-baeu-18-187-051baeu-19-187-05506301-rep/method-val-baeu-19-187-055-051-063-rep.pdf |
299 KB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/bioagilytix-baeu-18-187-051baeu-19-187-05506301-rep/method-val-baeu-18-187-051-19-187-055-06301-amend1.pdf |
545 KB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/intertek-ar-17-0175/method-val-intertek-ar-17-0175.pdf |
4.4 MB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/neogenomics-phar-valr-0279/method-val-neogenomics-phar-valr-0279.pdf |
2 MB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/neogenomics-phar-valr-0315/method-val-neogenomics-phar-valr-0315.pdf |
117 KB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/neogenomics-phar-valr-0334/method-val-neogenomics-phar-valr-0334.pdf |
117 KB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/neogenomics-phar-valr-0354/method-val-neogenomics-phar-valr-0354.pdf |
118 KB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/neogenomics-phar-valr-0415/method-val-neogenomics-phar-valr-0415.pdf |
107 KB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/neogenomics-phar-valr-0417/method-val-neogenomics-phar-valr-0417.pdf |
157 KB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/neogenomics-phar-valr-0425/method-val-neogenomics-phar-valr-0425.pdf |
1.8 MB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/neogenomics-phar-valr-0426/method-val-neogenomics-phar-valr-0426.pdf |
1.9 MB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/neogenomics-phar-valr-0427/method-val-neogenomics-phar-valr-0427.pdf |
1.3 MB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/neogenomics-phar-valr-0430/method-val-neogenomics-phar-valr-0430.pdf |
1.8 MB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/neogenomics-phar-verr-0019/method-val-neogenomics-phar-verr-0019.pdf |
2.2 MB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/neogenomics-tmf-ssp-0203/method-val-neogenomics-tmf-ssp-0203.pdf |
220 KB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/urmc-c19-001/method-val-urmc-c19-001.pdf |
190 KB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/urmc-c19-002/method-val-urmc-c19-002.pdf |
185 KB |
| 004480/0098/m5/53-clin-stud-rep/531-rep-biopharm-stud/5314-bioanalyt-analyt-met/urmc-sh-cp-ct-val-0026-0001a/method-val-urmc-sh-cp-ct-val-0026-0001a.pdf |
1.2 MB |
| 004480/0098/m5/53-clin-stud-rep/534-rep-human-pd-stud/5342-patient-pd-stud-rep/kte-c19-105-pk-pd/report-body.pdf |
26.7 MB |
| 004480/0098/m5/53-clin-stud-rep/534-rep-human-pd-stud/5342-patient-pd-stud-rep/kte-c19-105-pk-pd/statistical-methods.pdf |
289 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5351-stud-rep-contr/scholar-5/scholar-5-report-body.pdf |
2.2 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5351-stud-rep-contr/scholar-5/scholar-5-protocol.pdf |
330 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5351-stud-rep-contr/scholar-5/scholar-5-statistical-methods.pdf |
2.3 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/synopsis.pdf |
126 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/report-body.pdf |
33.9 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/protocol.pdf |
5.6 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/sample-crf.pdf |
2.3 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/iec-irb-list.pdf |
410 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/investigator-list.pdf |
128 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/signatures-investigators.pdf |
201 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/patient-list-by-batch.pdf |
149 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/audit-certificates.pdf |
469 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/statistical-methods.pdf |
2.5 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/list-discontinued-pts.pdf |
67 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/list-protocol-deviations.pdf |
186 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/list-pts-excluded-efficacy.pdf |
200 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/list-demographic-data.pdf |
303 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/list-comply-or-concentration.pdf |
232 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/list-efficacy-response.pdf |
4.5 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/list-adverse-events.pdf |
18.1 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105/list-labs-by-pts.pdf |
39.5 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/synopsis.pdf |
150 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/report-body.pdf |
106.7 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/narratives.pdf |
6.5 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/protocol.pdf |
2 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/sample-crf.pdf |
4 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/iec-irb-list.pdf |
343 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/investigator-list.pdf |
112 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/signatures-investigators.pdf |
202 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/patient-list-by-batch.pdf |
161 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/statistical-methods.pdf |
5 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/list-discontinued-pts.pdf |
43 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/list-protocol-deviations.pdf |
344 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/list-pts-excluded-efficacy.pdf |
208 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/list-demographic-data.pdf |
328 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/list-comply-or-concentration.pdf |
156 KB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/list-efficacy-response.pdf |
5.2 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/list-adverse-events.pdf |
28.3 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5352-stud-rep-uncontr/kte-c19-105-addendum/list-labs-by-pts.pdf |
36.6 MB |
| 004480/0098/m5/53-clin-stud-rep/535-rep-effic-safety-stud/rr-inhl/5353-rep-analys-data-more-one-stud/iss/iss-tfls.pdf |
20 MB |
| 004480/0098/m5/54-lit-ref/aliqopa-2020-uspi.pdf |
396 KB |
| 004480/0098/m5/54-lit-ref/andorsky-2019-jclinoncol-abstract.pdf |
2.1 MB |
| 004480/0098/m5/54-lit-ref/barr-2017-blood.pdf |
548 KB |
| 004480/0098/m5/54-lit-ref/batlevi-2020-bloodcancerj.pdf |
1.3 MB |
| 004480/0098/m5/54-lit-ref/bendamustinehydrochloride-2021-smpc.pdf |
463 KB |
| 004480/0098/m5/54-lit-ref/bendeka-2020-uspi.pdf |
183 KB |
| 004480/0098/m5/54-lit-ref/blincyto-2020-uspi.pdf |
435 KB |
| 004480/0098/m5/54-lit-ref/brudno-2018-natrevclinoncol.pdf |
824 KB |
| 004480/0098/m5/54-lit-ref/casulo-2015-jclinoncol.pdf |
159 KB |
| 004480/0098/m5/54-lit-ref/chang-2019-asgct-presentation.pdf |
999 KB |
| 004480/0098/m5/54-lit-ref/cheah-2018-bestpractresclinhaematol.pdf |
216 KB |
| 004480/0098/m5/54-lit-ref/cheson-2014-jclinoncol.pdf |
134 KB |
| 004480/0098/m5/54-lit-ref/cheson-2018-jclinoncol.pdf |
915 KB |
| 004480/0098/m5/54-lit-ref/copiktra-2019-uspi.pdf |
7.8 MB |
| 004480/0098/m5/54-lit-ref/copiktra-2021-smpc.pdf |
524 KB |
| 004480/0098/m5/54-lit-ref/dada-2019-eurjhaematol.pdf |
509 KB |
| 004480/0098/m5/54-lit-ref/denlinger-2018-cancermanagementres.pdf |
176 KB |
| 004480/0098/m5/54-lit-ref/dreyling-2017-jclinoncol.pdf |
851 KB |
| 004480/0098/m5/54-lit-ref/ekberg-2020-brjhaematol.pdf |
1.2 MB |
| 004480/0098/m5/54-lit-ref/evens-2013-cancer.pdf |
255 KB |
| 004480/0098/m5/54-lit-ref/fenske-2018-ascopost.pdf |
614 KB |
| 004480/0098/m5/54-lit-ref/flinn-2019-jclinoncol.pdf |
1.6 MB |
| 004480/0098/m5/54-lit-ref/freedman-2018-amjhematol.pdf |
665 KB |
| 004480/0098/m5/54-lit-ref/friedberg-2012-jclinoncol.pdf |
241 KB |
| 004480/0098/m5/54-lit-ref/garfall-2015-nengljmed.pdf |
1.2 MB |
| 004480/0098/m5/54-lit-ref/gazyva-2017-uspi.pdf |
795 KB |
| 004480/0098/m5/54-lit-ref/gazyva-2021-uspi.pdf |
674 KB |
| 004480/0098/m5/54-lit-ref/gazyvaro-2014-smpc.pdf |
913 KB |
| 004480/0098/m5/54-lit-ref/gazyvaro-2021-smpc.pdf |
1.3 MB |
| 004480/0098/m5/54-lit-ref/gopal-2014-nengljmed.pdf |
1.2 MB |
| 004480/0098/m5/54-lit-ref/gribben-2007-blood.pdf |
230 KB |
| 004480/0098/m5/54-lit-ref/gust-2017-cancerdiscov.pdf |
1.6 MB |
| 004480/0098/m5/54-lit-ref/hajek-2013-brjhaematol.pdf |
419 KB |
| 004480/0098/m5/54-lit-ref/imbruvica-2020-uspi.pdf |
1.1 MB |
| 004480/0098/m5/54-lit-ref/italiano-2018-lancetoncol.pdf |
268 KB |
| 004480/0098/m5/54-lit-ref/kahl-2008-hematologyamsoc.pdf |
98 KB |
| 004480/0098/m5/54-lit-ref/kahl-2016-blood.pdf |
901 KB |
| 004480/0098/m5/54-lit-ref/kritharis-2015-cancertreatres.pdf |
308 KB |
| 004480/0098/m5/54-lit-ref/kuperhommel-2013-leuklymphoma.pdf |
652 KB |
| 004480/0098/m5/54-lit-ref/kurth-2006-amjepidemiol.pdf |
119 KB |
| 004480/0098/m5/54-lit-ref/lee-2011-annalsofoncology.pdf |
280 KB |
| 004480/0098/m5/54-lit-ref/leguyaderpeyrou-2016-revepidemiolsantepublique.pdf |
263 KB |
| 004480/0098/m5/54-lit-ref/leonard-2019-jclinoncol.pdf |
1.5 MB |
| 004480/0098/m5/54-lit-ref/li-2013-exprevofanticancerther.pdf |
1014 KB |
| 004480/0098/m5/54-lit-ref/link-2019-brjhaematol.pdf |
161 KB |
| 004480/0098/m5/54-lit-ref/locke-2018-asco-abstract.pdf |
689 KB |
| 004480/0098/m5/54-lit-ref/luminari-2007-hematoloncol.pdf |
237 KB |
| 004480/0098/m5/54-lit-ref/luminari-2019-blood.pdf |
680 KB |
| 004480/0098/m5/54-lit-ref/lunning-2016-brjhaematol.pdf |
106 KB |
| 004480/0098/m5/54-lit-ref/mangal-2017-hematologicaloncol.pdf |
384 KB |
| 004480/0098/m5/54-lit-ref/maurer-2014-journalofclinicaloncology.pdf |
239 KB |
| 004480/0098/m5/54-lit-ref/maurer-2016-amjhematol.pdf |
696 KB |
| 004480/0098/m5/54-lit-ref/mclaughlin-1991-annoncol.pdf |
354 KB |
| 004480/0098/m5/54-lit-ref/mclaughlin-1998-jclinoncol.pdf |
480 KB |
| 004480/0098/m5/54-lit-ref/miller-2015-clincancerres.pdf |
148 KB |
| 004480/0098/m5/54-lit-ref/morschhauser-2019-blood-abstract.pdf |
633 KB |
| 004480/0098/m5/54-lit-ref/noy-2017-blood.pdf |
774 KB |
| 004480/0098/m5/54-lit-ref/revlimid-2019-smpc.pdf |
713 KB |
| 004480/0098/m5/54-lit-ref/revlimid-2019-uspi.pdf |
893 KB |
| 004480/0098/m5/54-lit-ref/robinson-2013-bonemarrowtransplant.pdf |
327 KB |
| 004480/0098/m5/54-lit-ref/sant-2010-blood.pdf |
386 KB |
| 004480/0098/m5/54-lit-ref/santomasso-2018-cancerdiscov.pdf |
1.7 MB |
| 004480/0098/m5/54-lit-ref/sehn-2016-lancetoncol.pdf |
148 KB |
| 004480/0098/m5/54-lit-ref/shi-2017-jclinoncol.pdf |
839 KB |
| 004480/0098/m5/54-lit-ref/sindel-2019-currtreatoptionsoncol.pdf |
219 KB |
| 004480/0098/m5/54-lit-ref/solal-celigny-2004-blood.pdf |
303 KB |
| 004480/0098/m5/54-lit-ref/tan-2013-blood.pdf |
735 KB |
| 004480/0098/m5/54-lit-ref/tazverik-2020-uspi.pdf |
232 KB |
| 004480/0098/m5/54-lit-ref/teixeiramendes-2017-bestpractresclinhaematol.pdf |
6.8 MB |
| 004480/0098/m5/54-lit-ref/thenonhodgkinslymphclassproj-1997-blood.pdf |
179 KB |
| 004480/0098/m5/54-lit-ref/thieblemont-2019-eha-posterps1262.pdf |
789 KB |
| 004480/0098/m5/54-lit-ref/ukoniq-2021-uspi.pdf |
505 KB |
| 004480/0098/m5/54-lit-ref/wang-2020-nengljmed.pdf |
306 KB |
| 004480/0098/m5/54-lit-ref/yescarta-2021-uspi.pdf |
430 KB |
| 004480/0098/m5/54-lit-ref/zinzani-2017-bestpractresclinhaematol.pdf |
6.7 MB |
| 004480/0098/m5/54-lit-ref/zucca-2020-annoncol.pdf |
327 KB |
| 004480/0098/m5/54-lit-ref/zydelig-2020-smpc.pdf |
1.5 MB |
| 004480/0098/m5/54-lit-ref/zydelig-2020-uspi.pdf |
623 KB |
| 004480/0098/index-md5.txt |
32 B |
| 004480/0098/index.xml |
61 KB |
| 004480/0098/m1/eu/eu-regional.xml |
8 KB |
| 004480/0098/util/style/ectd-2-0.xsl |
2 KB |
| 004480/0098/util/style/eu-regional.xsl |
25 KB |
| 004480/0098/util/dtd/eu-regional.dtd |
5 KB |
| 004480/0098/util/dtd/eu-leaf.mod |
2 KB |
| 004480/0098/util/dtd/eu-envelope.mod |
3 KB |
| 004480/0098/util/dtd/ich-ectd-3-2.dtd |
31 KB |
| 004480/0098-workingdocuments/1.8.2 Risk Management System Annex 6.docx |
132 KB |
| 004480/0098-workingdocuments/1.8.2 Risk Management System.docx |
1.6 MB |
| 004480/0098-workingdocuments/2.7.6 Synopses of Individual Studies - ZUMA-5.docx |
43 KB |
| 004480/0098-workingdocuments/2.6.1 Introduction - ZUMA-5.docx |
707 KB |
| 004480/0098-workingdocuments/2.6.7 Toxicology Tabulated Summary - ZUMA-5.docx |
79 KB |
| 004480/0098-workingdocuments/1.8.2 Risk Management System Annex 3.docx |
38 KB |
| 004480/0098-workingdocuments/2.7.4 Summary of Clinical Safety - ZUMA-5.docx |
485 KB |
| 004480/0098-workingdocuments/2.7.2 Summary of Clinical Pharmacology Studies - ZUMA-5.docx |
651 KB |
| 004480/0098-workingdocuments/ema-combined-h-4480-en-annotated.docx |
244 KB |
| 004480/0098-workingdocuments/1.8.2 Risk Management System Annex 6 - Annotated.docx |
134 KB |
| 004480/0098-workingdocuments/ema-combined-h-4480-en.docx |
227 KB |
| 004480/0098-workingdocuments/2.6.6 Toxicology Written Summary - ZUMA-5.docx |
194 KB |
| 004480/0098-workingdocuments/2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods - ZUMA-5.docx |
76 KB |
| 004480/0098-workingdocuments/2.5 Clinical Overview - ZUMA-5.docx |
2.8 MB |
| 004480/0098-workingdocuments/2.4 Nonclinical Overview - ZUMA-5.docx |
765 KB |
| 004480/0098-workingdocuments/1.8.2 Risk Management System Annex 3 - Annotated.docx |
39 KB |
| 004480/0098-workingdocuments/1.8.2 Risk Management System - Annotated.docx |
1.9 MB |
| 004480/0098-workingdocuments/1.8.2 Risk Management System Annex 2 - Annotated.docx |
40 KB |
| 004480/0098-workingdocuments/1.8.2 Risk Management System Annex 2.docx |
38 KB |
| 004480/0098-workingdocuments/2.2 Introduction - ZUMA-5.docx |
62 KB |
| 004480/0098-workingdocuments/2.7.3 Summary of Clinical Efficacy - ZUMA-5.docx |
2.1 MB |
| 004480/0098-workingdocuments/2.7.5 Literature References - ZUMA-5.docx |
51 KB |
Magnet link